Biophytis SAChange company Symbol lookupSelect an option...BPTS Biophytis SAJGGC Jaguar Global Growth Corporation IWHG Westwood Holdings Group IncBNOX Bionomics LtdPSO Pearson PLCERNA Eterna Therapeutics IncINDP Indaptus Therapeutics IncTSLX Sixth Street Specialty Lending IncWAVD Wavedancer IncSGBX Safe & Green Holdings CorpGo
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Based in France
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
American Depositary Receipt (ADR) Fee
ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2023. All rights reserved.